Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bundibugyo virus disease: transmission dynamics, infectiousness and viral persistence.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Kinetics of the humoral and cellular immune response up to 1 year from mpox virus infection.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025
Same author

Streamlining Global Germplasm Exchange: Integrating Scientific Rigor and Common Sense to Exclude Phantom Agents from Regulation.

Plant disease·2025
Same author

Cascade of care for TB infection in persons newly diagnosed with HIV in Italy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Ironing out the Links: Ferroptosis in epilepsy and SUDEP.

Epilepsy & behavior : E&B·2024
Same author

Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak.

The Journal of infection·2022
Same journal

β-Hydroxybutyrate Exposure is Associated with Increased TH<sup>+</sup> Neuron Abundance and Dopaminergic-Related Transcriptional Features in Human Midbrain Organoids.

Cellular and molecular neurobiology·2026
Same journal

The Diagnostic and Therapeutic Value of Micro-RNA in Parkinson's Disease.

Cellular and molecular neurobiology·2026
Same journal

An Engineered Multifunctional Fusion Protein Targeting Aβ Oligomers, Microglia and Autophagy Ameliorates Cognitive Deficits and Amyloid Pathology in Alzheimer's Disease Mice.

Cellular and molecular neurobiology·2026
Same journal

Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.

Cellular and molecular neurobiology·2026
Same journal

Loss of miR-204 Drives NPTX1-Dependent Mitochondrial Dysfunction and Neuronal Degeneration in Alzheimer's Disease.

Cellular and molecular neurobiology·2026
Same journal

Prdm15 Deficiency Results in Impaired Hippocampal Neurogenesis and Autism-Like Behaviors.

Cellular and molecular neurobiology·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

3-mercaptopropionic acid-induced seizures decrease NR2B expression in Purkinje cells: cyclopentyladenosine effect.

E Girardi1, J Auzmendi, N Charó

  • 1Instituto de Biología Celular y Neurociencia, Facultad de Medicina, Universidad de Buenos Aires and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Paraguay 2155, Buenos Aires, Argentina. egirardi@retina.ar

Cellular and Molecular Neurobiology
|July 14, 2010
PubMed
Summary
This summary is machine-generated.

Cyclopentyladenosine (CPA) reduces N-methyl-D-aspartate receptor 2B (NR2B) expression in the cerebellum following seizures. CPA combined with 3-mercaptopropionic acid (MP) treatment shows a tendency to restore NR2B levels, mitigating MP-induced convulsant effects.

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 11, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Cerebellar epileptic activity involves complex inhibitory mechanisms.
  • N-methyl-D-aspartate receptors (NMDARs), crucial for excitatory transmission, are implicated in neurological disorders.
  • The NR2B subunit of NMDARs is specifically expressed in mature Purkinje cells and may be affected during excitotoxicity.

Purpose of the Study:

  • To investigate the expression of the NR2B subunit in the cerebellum after induced seizures.
  • To determine the effect of cyclopentyladenosine (CPA), an adenosine analogue, on NR2B expression.
  • To evaluate the combined effect of CPA and 3-mercaptopropionic acid (MP) on NR2B expression and seizure activity.

Main Methods:

  • Repetitive seizures were induced in rats using 3-mercaptopropionic acid (MP).
  • Cyclopentyladenosine (CPA) was administered alone or prior to MP.
  • NR2B expression was analyzed in the whole cerebellum and Purkinje cells using Western blot and immunohistochemistry.

Main Results:

  • MP and CPA administration significantly decreased NR2B expression in the whole cerebellum.
  • Immunohistochemical analysis revealed a 55% decrease in NR2B in Purkinje cells after MP and a 12% decrease after CPA.
  • Combined CPA + MP treatment showed a tendency towards NR2B level recovery and a reduced effect of MP-induced convulsions.

Conclusions:

  • Repetitive seizures induced by MP alter NR2B expression in the cerebellum.
  • CPA administration affects NR2B expression, potentially as a protective mechanism against excitotoxicity.
  • The combined CPA + MP treatment may offer a neuroprotective strategy by modulating NR2B expression and reducing seizure severity.